[4-(3,5-Dimethylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone → HCID 71253082, 화합물

HRID 2411388노트

반응식

HRID 2411388 반응식
[CH2:1]([C@@H:3]1[CH2:7][CH2:6][S:5](=[O:9])(=[O:8])[NH:4]1)[CH3:2].[CH3:10][C:11]1[C:12]([N:18]2[CH2:23][CH2:22][N:21]([C:24]([C:26]3[CH:31]=[CH:30][C:29](I)=[CH:28][CH:27]=3)=[O:25])[CH2:20][CH2:19]2)=[N:13][CH:14]=[C:15]([CH3:17])[CH:16]=1>>[CH3:10][C:11]1[C:12]([N:18]2[CH2:19][CH2:20][N:21]([C:24]([C:26]3[CH:31]=[CH:30][C:29]([N:4]4[C@H:3]([CH2:1][CH3:2])[CH2:7][CH2:6][S:5]4(=[O:9])=[O:8])=[CH:28][CH:27]=3)=[O:25])[CH2:22][CH2:23]2)=[N:13][CH:14]=[C:15]([CH3:17])[CH:16]=1

참가 물질

3

반응물 2

HCID 58484535[4-(3,5-Dimethylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanoneHCID 86676750HCID 86676750, 화합물

생성물 1

HCID 71253082HCID 71253082, 화합물수율 12.9%

실험 절차

Using (R)-3-ethylisothiazolidine 1,1-dioxide (150 mg) described in Preparation Example 3 and [4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone (421 mg) described in Preparation Example 113 and by the reaction and treatment in the same manner as in Example 1, the title compound (57 mg) was obtained.

후처리

  1. customdescribed in Preparation Example 113 and by the reaction and treatment in the same manner as in Example 1

출처 및 근거

ORD 기록
ord-bfbd4945fcde464685b19661fcd24763
출처 데이터셋
uspto-grants-2014_08
특허 번호
US08816079B2

반응 노트

불러오는 중…